Insights

Gathering insights about ROVA…

Similar companies to ROVA

ROVA Tech Stack

ROVA uses 8 technology products and services including Open Graph, Webpack, Squarespace Commerce, and more. Explore ROVA's tech stack below.

Open Graph
Content Management System
Webpack
Development
Squarespace Commerce
E-commerce
JSON-LD
Javascript Frameworks
Stimulus
Javascript Frameworks
Modernizr
Javascript Libraries
Priority Hints
Performance
Adobe Fonts
Web Fonts

Media & News

Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 0.5% – Here’s Why
Aerovate Therapeutics, Inc. (NASDAQ: AVTE - Get Free Report) dropped 0.5% during mid-day trading on Friday. The company traded as low as $12.30 and last traded at $12.48. Approximately 136,019 shares were traded during mid-day trading, an increase of 994% from the average daily volume of 12,438 shares. The stock had previously closed at $12.54.
Nov 29, 2025 | www.defenseworld.net
Reviewing Aerovate Therapeutics (NASDAQ:AVTE) & Graybug Vision (NASDAQ:GRAY)
Volatility and Risk Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Earnings and Valuation This table compares Aerovate Therapeutics and Graybug Vision"s
Nov 05, 2025 | www.defenseworld.net
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC bought a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,564 shares of the company’s stock, valued at approximately $52,000. Squarepoint Ops LLC owned approximately 0.07% of Aerovate Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other institutional investors and hedge funds have also made changes to their positions in AVTE. Braidwell LP bought a new stake in shares of Aerovate Therapeutics during the fourth quarter valued at approximately $3,817,000. ADAR1 Capital Management LLC boosted its stake in shares of Aerovate Therapeutics by 720.7% during the 4th quarter. ADAR1 Capital Management LLC now owns 928,016 shares of the company’s stock worth $2,459,000 after acquiring an additional 814,941 shares during the last quarter. Allostery Investments LP purchased a new position in shares of Aerovate Therapeutics during the 4th quarter valued at $2,254,000. Affinity Asset Advisors LLC lifted its stake in shares of Aerovate Therapeutics by 33.3% during the 4th quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company’s stock valued at $2,120,000 after buying an additional 200,000 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Aerovate Therapeutics in the 4th quarter valued at $1,590,000. Aerovate Therapeutics Stock Performance Shares of NASDAQ AVTE opened at $7.71 on Wednesday. The company has a market cap of $223.47 million, a P/E ratio of -2.58 and a beta of 0.95. The firm’s fifty day moving average is $40.11 and its two-hundred day moving average is $71.98. Aerovate Therapeutics, Inc. has a 52-week low of $43.75 and a 52-week high of $884.98. Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) last posted its earnings results on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($10.50) by $7.35. As a group, analysts forecast that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year. Aerovate Therapeutics Announces Dividend The company also recently declared a dividend, which was paid on Monday, April 28th. Investors of record on Friday, April 25th were paid a dividend of $84.00 per share. The ex-dividend date of this dividend was Tuesday, April 29th. Aerovate Therapeutics Profile (Free Report) Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Jun 11, 2025 | www.defenseworld.net
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
Company is advancing portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Lead candidate JADE-001 on track to enter the clinic in second half of 2025, with initial data expected in first half of 2026 The combined company will operate as “Jade Biosciences, Inc.” and will trade on Nasdaq under the ticker symbol “JBIO” SAN FRANCISCO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the completion of its previously announced merger with Aerovate Therapeutics, Inc. (“Aerovate”). The combined company will operate as Jade Biosciences, Inc., with its shares expected to begin trading on the Nasdaq Capital Market on April 29, 2025, under the ticker symbol “JBIO.
Apr 28, 2025 | www.globenewswire.com
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass. , April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger.
Apr 21, 2025 | www.prnewswire.com
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share WALTHAM, Mass. , April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement").
Apr 09, 2025 | www.prnewswire.com
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass. , April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate.
Apr 07, 2025 | www.prnewswire.com

ROVA's Email Address Formats

ROVA uses at least 1 format(s):

ROVA Email Formats	Example	Percentage
FirstL@rova.com	JohnD@rova.com	40%
First@rova.com	John@rova.com	33%
Last@rova.com	Doe@rova.com	14%
FLast@rova.com	JDoe@rova.com	13%

Frequently Asked Questions

What is ROVA's stock symbol?

ROVA is a publicly traded company; the company's stock symbol is AVTE.

What is ROVA's official website and social media links?

ROVA's official website is rova.com and has social profiles on LinkedIn.

What is ROVA's NAICS code?

ROVA's NAICS code is 5112 - Software Publishers.

How many employees does ROVA have currently?

As of December 2025, ROVA has approximately 39 employees across 3 continents, including North AmericaEuropeAfrica. Key team members include Founder And Ceo: J. B.Junior Partner: C. N.Partner: S. A.. Explore ROVA's employee directory with LeadIQ.

What industry does ROVA belong to?

ROVA operates in the Software Development industry.

What technology does ROVA use?

ROVA's tech stack includes Open GraphWebpackSquarespace CommerceJSON-LDStimulusModernizrPriority HintsAdobe Fonts.

What is ROVA's email format?

ROVA's email format typically follows the pattern of FirstL@rova.com. Find more ROVA email formats with LeadIQ.

When was ROVA founded?

ROVA was founded in 1995.

ROVA

Q: What is ROVA's official website and social media links?

ROVA's official website is rova.com. ROVA has social profiles on LinkedIn.

Q: How many employees does ROVA have currently?

ROVA has approximately 39 employees.

Q: What technology does ROVA use?

ROVA's tech stack includes Priority Hints, Squarespace Commerce, Adobe Fonts, Webpack, X-Content-Type-Options.

Software DevelopmentNew York, United States11-50 Employees

Rova provides software that reduces the cost and complexity for large enterprises to deliver secure mobile workforce solutions. Its flagship product, Rova Enterprise, enables traveling employees to easily and securely connect to corporate networks, applications, and information.

Rova has for more than a decade delivered enterprise mobility software to Fortune 1000 companies.

Currently, ROVA enterprise is hosted, re-branded and sold though one of the world's largest telecommunications companies, and is its primary cloud-based enterprise mobility platform.  Since its launch late last year, we have jointly added many customers, including a 50,000 user manufacturer, several 30,000+ financial services comapnies, and many more of varying sizes.